Effector Therape -CW27EFTRWPreferred / convertible
13F holders, Q2 2024 (June 30)12holders
0new positions
0sold out
$0.00avg. 13F price*
At the end of Q2 2024, 12 institutions reported holding Effector Therape -CW27 (EFTRW) in their 13F filings, unchanged from Q1 2024. 0 opened new positions and 0 sold out. The largest holders were Aristeia Capital, L.L.C. ($2K), Goldman Sachs Group Inc. ($757) and Whitebox Advisors LLC ($358).
- Company
- Effector Therape -CW27
- CUSIP
- 28202V116
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 255,174 shares bought and 35,016 shares sold, net +220,158 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 12 holders
| Aristeia Capital, L.L.C. | — | Reduce -2.2% | 1,303,646 | $2K |
| Goldman Sachs Group Inc. | — | No change | 630,539 | $757 |
| Whitebox Advisors LLC | — | No change | 298,145 | $358 |
| Susquehanna International Group, LLP | — | Add +1094.2% | 200,557 | $241 |
| MMCAP International Inc. SPC | — | No change | 145,941 | $175 |
| Parallel Advisors, LLC | — | No change | 64,166 | $77 |
| UBS Group AG | — | Add +9782.8% | 63,645 | $64 |
| III Capital Management | — | Reduce -12.5% | 36,579 | $45 |
| TENOR CAPITAL MANAGEMENT Co., L.P. | — | No change | 33,333 | $40 |
| Wolverine Asset Management LLC | — | Add +85.6% | 18,239 | $21 |
| Tower Research Capital LLC (TRC) | — | No change | 23 | $0 |
| Pineridge Advisors LLC | — | No change | 33 | $0 |
"% of holder's portfolio" is EFTRW's weight in each manager's 13F, not the share of Effector Therape -CW27 the manager owns.